| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2005 | US20050113365 Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
| 05/26/2005 | US20050113364 Reacting 3-ethoxy-4-hydroxyphenylacetic acid propyl ester with a compound of the formula X CH2C( .dbd. O)N(CH2CH3)2, wherein X is a leaving group, in the presence of a base to form [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester |
| 05/26/2005 | US20050113362 Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 05/26/2005 | US20050113361 Amide derivatives as NMDA receptor antagonists |
| 05/26/2005 | US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 05/26/2005 | US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone |
| 05/26/2005 | US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders |
| 05/26/2005 | US20050113357 Cholinergic agents such as 3-[3-(4-methoxypiperidine)-1-yl-propyl]-1H-indole; for therapy of cognitive dysfunction, forgetfulness, confusion, memory loss, attention deficits, deficits in visual perception, depression, pain, sleep disorders, and psychosis |
| 05/26/2005 | US20050113356 Inhibitors of cathepsin S |
| 05/26/2005 | US20050113355 Suspending cefdinir in pyridine; salt formation |
| 05/26/2005 | US20050113354 Bioavailable prodrugs of androgenic steroids and related method |
| 05/26/2005 | US20050113353 Applying gel containing testosterone |
| 05/26/2005 | US20050113351 Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| 05/26/2005 | US20050113350 hormonal treatment over a desired period of time longer than 21-28 days; inhibiting ovulation in human; birth control |
| 05/26/2005 | US20050113348 for controlling renin production and blood pressure |
| 05/26/2005 | US20050113347 Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
| 05/26/2005 | US20050113346 making sulfur compounds such as 2-((4-But-2-ynyloxy-benzenesulfonyl)-methyl-amino)-N-hydroxy-3-methyl -butyramide, used as tumor necrosis factor-alpha converting enzyme (TACE) inhibitors, for prophylaxis of rheumatic diseases, sepsis or inflammation |
| 05/26/2005 | US20050113345 Amidoalkyl phosphates, e.g., 3-(lauramido-3-hexylpropoxy)-2-lauramidopropyl 2-([3-p-hydroxyphenyl)-2-carboxypropionylamino]ethyl phosphate; used for treating inflammatory conditions such as inflammatory bowel disease and for identifying agents that inhibit activation of Toll-like receptor 2 |
| 05/26/2005 | US20050113344 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| 05/26/2005 | US20050113343 Solid-state form of alendronate sodium and preparation thereof |
| 05/26/2005 | US20050113341 Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis |
| 05/26/2005 | US20050113340 9-(Substituted aryl, heteroaryl, alicyclyl, or heterocyclyl)methyl-2-amino-6-halopurines, e.g., 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine; used in the treatment and prevention of various Heat Shock Protein 90 mediated disorders, e.g., proliferative disorders |
| 05/26/2005 | US20050113339 inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorder, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, and malignant disease |
| 05/26/2005 | US20050113338 Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| 05/26/2005 | US20050113337 Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin |
| 05/26/2005 | US20050113335 Which enhances fertility via causing oocyte release from the ovary; colony stimulating factors; |
| 05/26/2005 | US20050113334 Composition and method |
| 05/26/2005 | US20050113333 Comprises caffeic acid, chlorogenic acid, and/or ferulic acid, water-soluble and fermentable dietary fiber (alginate, polydextrose) |
| 05/26/2005 | US20050113332 Compositions and methods for treating an arthritic condition |
| 05/26/2005 | US20050113331 Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors |
| 05/26/2005 | US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization |
| 05/26/2005 | US20050113328 Method and antisense compound for potentiating anti-cancer agents |
| 05/26/2005 | US20050113326 Gene expression inhibition; connective tissue growth factor modulators; nucleosides, phosphorothioate/phosphodiester linkages; metabolic diseases, diabetes |
| 05/26/2005 | US20050113324 For treatment/prevention of cancer; retrotransposons; enzyme inhibitors/antagonists (antisense agents, nucleoside analog 3'-azido-2',3'-dideoxythymidine) block lengthening of telomeres in telomerase negative cells; gene expression inhibition; host cells; kits |
| 05/26/2005 | US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries |
| 05/26/2005 | US20050113321 DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor |
| 05/26/2005 | US20050113320 Use of calphostin C to treat drug-resistant tumor cells |
| 05/26/2005 | US20050113319 11-Deoxy-6,9-ether erythromycin compounds |
| 05/26/2005 | US20050113318 Such as salmeterol or formoterol; low amounts of active agents, less prone to detrimental side effects |
| 05/26/2005 | US20050113316 Process for producing dammarane sapogenins and ginsenosides |
| 05/26/2005 | US20050113314 For treating microalbuminuria, nephropathies, retinopathies, and erectile dysfunction; side effect reduction |
| 05/26/2005 | US20050113312 2-0-(-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containning compositions comprising it |
| 05/26/2005 | US20050113311 Comprises N-alpha-acetyl-L-histidine; kits; droppers |
| 05/26/2005 | US20050113310 Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases |
| 05/26/2005 | US20050113307 Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| 05/26/2005 | US20050113306 For inhibition of bone metastases in prostate cancer patients |
| 05/26/2005 | US20050113303 Method for treating metabolic bone disease such as osteomalacia and osteoporosis in a patient by administering a compound that modulates phosphate regulating endopeptidase homolog (PEX) expression and/or PEX enzymatic activity |
| 05/26/2005 | US20050113301 Administering calcitonin and dehydroepiandrosterone (DHEA) to patient being treated for systemic lupus erythematosus where the immunosuppressant tends to reduce bone mineral density(BMD); osteoporosis |
| 05/26/2005 | US20050113295 Carboxamide and amino derivatives and methods of their use |
| 05/26/2005 | US20050113294 Carboxamide and amino derivatives and methods of their use |
| 05/26/2005 | US20050113293 Cyclic and linear oligopeptides; capable of increasing gap junction conductance; lack the proarrhythmic side effects; use as drug to also treat eye disorders, cancer, and gastrointestinal disorders among others |
| 05/26/2005 | US20050113287 Composition to enhance joint function and repair |
| 05/26/2005 | US20050113286 Methods for treating congestive heart failure |
| 05/26/2005 | US20050113283 Methods of treating conditions associated with an EDG-4 receptor |
| 05/26/2005 | US20050113276 Skin cleaning compounds, body splash, surgical scrub, wound care agents, hand sanitizers, disinfectants, mouthwashes, pet shampoos, hard surface sanitizer; reduction of bacteria, rotavirus, or rhinovirus on skin surface; topical |
| 05/26/2005 | US20050113012 Reducing microorganisms in food |
| 05/26/2005 | US20050112738 Process for preparation of (6S,9R)-11-OXO-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene |
| 05/26/2005 | US20050112717 Using solution containing nitric oxide synthase for synthesis of nitrogen oxide ; adding guanylate cyclase and guanosine triphosphate which allow synthesis of cyclic guanosine, 3',5'-monophosphate; measurement amount of cyclic guanosine 3',5'-monophosphate using antibodies |
| 05/26/2005 | US20050112681 Isolated human transporter proteins, nucleic acid molecules encoding human, transporter proteins, and uses thereof |
| 05/26/2005 | US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies |
| 05/26/2005 | US20050112668 Determination sensitivity for development fat metabolism diosrders by comparison of gene expression levels |
| 05/26/2005 | US20050112638 Screening agent that moderates post-transcriptional control of angiotensin receptors; hypotensive agents |
| 05/26/2005 | US20050112627 Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics |
| 05/26/2005 | US20050112568 Dgks as modifiers of the p53 pathwha and methods of use |
| 05/26/2005 | US20050112563 Sub-sequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme; diagnostics; antisense therapeutics |
| 05/26/2005 | US20050112556 Drug screening; endogenous human retrovirus; protein or peptide expressed by said retrovirus |
| 05/26/2005 | US20050112266 Improved bioavailability; dairy products, sauces; antioxidant activity in ameliorative/preventive efficacy in hypercholesterolemia, hyperlipemia and atherosclerosis |
| 05/26/2005 | US20050112214 Method for reducing acne for improving skin tone |
| 05/26/2005 | US20050112213 Compositions of improved sucralfate and sucrose octasulfate and method of use |
| 05/26/2005 | US20050112212 Herbal formulation |
| 05/26/2005 | US20050112210 Age-related macular degeneration; include vitamins, minerals, and antioxidants such as vitamins A, C, E, zinc, lutein and zeaxanthin |
| 05/26/2005 | US20050112208 Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation |
| 05/26/2005 | US20050112207 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112205 Method of encapsulating an active substance |
| 05/26/2005 | US20050112204 micellar poloxamer preparation comprising voriconazole and a single poloxamer; increases solubility and aqueous stability |
| 05/26/2005 | US20050112202 tableting processes and equipment, and improved solid dosage forms for oral delivery of drugs that cause contact irritation or ulceration to the lining of the esophagus and stomach |
| 05/26/2005 | US20050112200 improved absorption, bioavailabilty and/or half-life ; treatment or prevention of atherosclerosis or for the treatment of heavy metal accumulation |
| 05/26/2005 | US20050112199 Therapeutic regimens for administering drug combinations |
| 05/26/2005 | US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics |
| 05/26/2005 | US20050112196 Of water insoluble or poorly soluble neurological agent such as antipsychotic agent or antidepressant e.g. olanzapine, mirtazepine, or risperidone that dissolves in the buccal cavity and has a total weight of less than 500 milligrams |
| 05/26/2005 | US20050112195 Dosage form comprising core of first drug and a coating of a second insoluble drug, hydroxypropyl cellulose, and a water soluble film former of hydroxypropyl methylcellulose, copovidone, and/or a film-forming agent that forms a solid solution with the second drug; organic solvent-free coating |
| 05/26/2005 | US20050112193 Immediate-release formulations of acid-labile pharmaceutical compositions |
| 05/26/2005 | US20050112192 Process for preparing formulations of lipid-regulating drugs |
| 05/26/2005 | US20050112190 Dosage form for controlled release of an active agent formulation |
| 05/26/2005 | US20050112188 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 05/26/2005 | US20050112187 Nucleic acid that expresses a polypeptide such as a cytokine and a phospholipid, both having cytotoxic activity; synergistic combination; side effect reduction |
| 05/26/2005 | US20050112186 Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means |
| 05/26/2005 | US20050112181 By transdermal administration of testosterone in a hydroalcoholic gel; unique pharmacokinetic steady-state profile |
| 05/26/2005 | US20050112179 Method to reduce stool odor of companion animals |
| 05/26/2005 | US20050112178 Kit for cleaning the digestive tract e.g. prior to colonoscopy or surgical procedure; provides calories for daily routine while minimizing stool formation |
| 05/26/2005 | US20050112175 Drug delivery device |
| 05/26/2005 | US20050112158 Method for synthesis of silylated ascorbic acid derivatives |
| 05/26/2005 | US20050112147 Administering a neurotoxin |
| 05/26/2005 | US20050112129 Compositions and methods for the diagnosis and treatment of tumors of glial origin |
| 05/26/2005 | US20050112128 Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure |
| 05/26/2005 | US20050112123 Methods of treating proteinuria |
| 05/26/2005 | US20050112111 Microbiological culturein aqueous solution containing nutrients; probiotic activity |
| 05/26/2005 | US20050112110 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators |
| 05/26/2005 | US20050112100 Sp1 and Sp3 targeted cancer therapies and therapeutics |